Dry And Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast
The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors: Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis, and Regeneron / Bayer HealthCare / Santen’s Eylea. Roche’s Susvimo (ranibizumab PDS), which launched in November 2021 in the United States, will also attract a small patient share because of its less frequent dosing regimen of once every six months. Additionally, we expect Roche / Chugai’s Vabysmo (faricimab), which launched in the United States in February 2022 and was approved in Japan in March 2022, will see strong uptake driven by its new mechanism of action (MOA) and advantageous dosing regimen. Vabysmo was approved by the FDA in January 2022, making it the first bispecific antibody to launch in the ophthalmology space. Nevertheless, the mainstay anti-VEGF therapies will face competition from the growing number of therapies for wet AMD in the late-phase pipeline, including biosimilar agents. In contrast to wet AMD, the management of dry AMD is limited because no prescription therapies are approved for this large subpopulation. Despite recent setbacks in the clinical development of some late-phase dry AMD therapies, other agents are progressing, such as Apellis’s pegcetacoplan and Iveric Bio’s Zimura, increasing the likelihood that an effective therapy may soon emerge.
QUESTIONS ANSWERED
- How will the wet AMD treatment algorithm change as new products launch?
- To what extent will novel therapies such as Roche’s ranibizumab PDS and faricimab capitalize on the need for therapies with longer dosing intervals than those currently offered?
- How receptive are retinal specialists to novel gene therapy approaches, to biosimilar agents for wet AMD, and to emerging therapies for GA?
CONTENT HIGHLIGHTS
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 31 country-specific interviews with thought-leading retinal specialists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Total prevalence of late AMD by country, segmented by GA and wet AMD subpopulations, including diagnosed and drug-treated rates.
Forecast: 10-year, annualized, drug-level sales and patient share of key GA and wet AMD therapies through 2030, segmented by brands / biosimilars and epidemiological subpopulations.
Emerging therapies: Phase III / PR: 8 drugs; Phase II: 15 drugs; coverage of select Phase I products.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Table of contents
- Dry And Wet Age-Related Macular Degeneration - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Dry and Wet Age-Related Macular Degeneration - Key Findings - June 2022
- Key Updates
- Q3 2022
- July 2022
- Q2 2022
- June 2022
- May 2022
- May 2022
- April 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- Q4 2021
- December 2021
- November 2021
- Q3 2021
- September 2021
- July 2021
- Q2 2021
- June 2021
- May 2021
- April 2021
- Q3 2022
- Market Outlook
- Key Findings
- Market share of drug classes for AMD: 2020
- Market share of drug classes for AMD: 2030
- Dry and Wet AMD SWOT Analysis
- Market Drivers and Constraints
- What Factors Are Driving the Market for AMD?
- What Factors Are Constraining the Market for AMD?
- Major-market sales and treated patients in AMD: 2020-2030
- Major-market brand and biosimilar sales and market share for VEGF Inhibitors in wet AMD: 2020-2030
- Market share and share of treated patients for wet AMD by region: 2020-2030
- Drug Class-Specific Trends
- Patient share of VEGF inhibitors in wet AMD in the United States: 2020-2030
- Patient share of VEGF inhibitors in wet AMD in Europe: 2020-2030
- Patient share of VEGF inhibitors in wet AMD in Japan: 2020-2030
- Major-market sales of VEGF inhibitors in wet AMD: 2020-2030
- Patient share of faricimab in wet AMD in the major markets: 2020-2030
- Major-market sales of faricimab in wet AMD: 2020-2030
- Sales of complement system inhibitors in GA in the United States: 2020-2030
- Patient share of complement system inhibitors in GA in the United States: 2020-2030
- Sales of complement system inhibitors in GA in Europe: 2020-2030
- Patient share of complement system inhibitors in GA in Europe: 2020-2030
- Key Findings
- Forecast
- Market Forecast Downloads
- Market Forecast Assumptions u2013 Dry and Wet Age-Related Macular Degeneration (2020-2030) u2013 June 2022
- Market Forecast Dashboard - Dry and Wet Age-Related Macular Degeneration (2020-2030) - June 2022
- Etiology and Pathophysiology
- Disease Overview
- Pathophysiology
- Disease Classifications
- Anatomy of the Eye
- Pathology
- Etiology
- Mechanisms Associated with AMD Pathogenesis
- Risk Factors
- Genetic Risk Factors
- Genetic Markers Associated With AMD
- Other Risk Factors
- Demographic and Environmental Risk Factors Associated With AMD
- Key Pathways and Drug Targets
- Potential Drug Targets for AMD
- Disease Overview
- Epidemiology
- Key Findings
- Epidemiology Populations
- Disease Definition
- Methods
- Sources Used for Total Prevalent Cases of Late AMD
- Total Prevalent Cases of Late AMD: 2020-2030 (Thousands)
- Disease Definition
- Methods
- Sources Used for Total Prevalent Cases of GA and Wet AMD
- Total Prevalent Cases of GA and Wet AMD: 2020-2030 (Thousands)
- Diagnosed Prevalent Cases of Wet AMD: 2020-2030 (Thousands)
- Diagnosed Prevalent Cases of GA: 2020-2030 (Thousands)
- Drug-Treated Wet AMD Cases: 2020-2030 (Thousands)
- Drug-Treated GA Cases: 2020-2030 (Thousands)
- Key Findings
- Current Treatment
- Key Findings
- Treatment Goals
- Key Endpoints Used in Clinical Trials for AMD
- Imaging Techniques Used in Evaluating AMD
- Key Current Therapies
- Overview
- Mechanism of Action of Key Current Drug Classes Used for Wet AMD
- Current Treatments Used for Wet AMD
- Dosing Regimens as Indicated in the Labels of Key VEGF Inhibitors Approved for the Treatment of Wet AMD by Region
- Commonly Used Treatment Regimens for VEGF Inhibitors in Wet AMD in Clinical Practice
- Market Events Impacting the Use of Key Current Therapies in AMD
- Advantages and Disadvantages of Lucentis
- Expert Insight on Lucentis
- Advantages and Disadvantages of Eylea
- Expert Insight on Eylea
- Advantages and Disadvantages of Avastin
- Expert Insight on Avastin
- Advantages and Disadvantages of Beovu
- Key Results From Select Clinical Trials Investigating Beovu for the Treatment of Wet AMD
- Ongoing Clinical Development of Beovu
- Key Ongoing Clinical Trials of Beovu in the Treatment of Wet AMD
- Expert Insight on Beovu
- Susvimo
- Advantages and Disadvantages of Susvimo
- Key Results From Select Clinical Trials Investigating Susvimo for the Treatment of Wet AMD
- Ongoing Clinical Development of Susvimo
- Key Ongoing Clinical Trials of Susvimo in the Treatment of Wet AMD
- Expert Insight: Susvimo
- Vabysmo
- Advantages and Disadvantages of Vabysmo
- Key Results From Select Clinical Trials Investigating Vabysmo for the Treatment of Wet AMD
- Ongoing Clinical Development of Vabysmo
- Key Ongoing Clinical Trials of Vabysmo in the Treatment of Wet AMD
- Expert Insight: Vabysmo
- Advantages and Disadvantages of Visudyne / Photodynamic Therapy
- Medical Practice
- Overview
- Country-Specific AMD Treatment Guidelines
- Factors Influencing Drug Selection in Wet AMD
- Treatment Decision Tree for AMD: United States
- Treatment Decision Tree for AMD: Europe
- Treatment Decision Tree for AMD: Japan
- Key Findings
- Unmet Need Overview
- Current and Future Attainment of Unmet Needs in AMD
- Top Unmet Needs in AMD: Current and Future Attainment
- Expert Insight: Unmet Need in AMD
- Drug Pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging Therapies
- Key Findings
- Pipeline trends in AMD
- Key Emerging Therapies
- Key Therapies in Development for AMD
- Estimated Launch Dates of Key Emerging Therapies for the Treatment of AMD
- ONS-5010 Profile
- Analysis of the Clinical Development Program for ONS-5010
- Expert Insight: ONS-5010
- Expectations for Launch and Sales Opportunity of ONS-5010 in Wet AMD
- High-Dose Aflibercept Profile
- Analysis of the Clinical Development Program for High-Dose Aflibercept
- Expert Insight: High-Dose Aflibercept
- Expectations for Launch and Sales Opportunity of High-Dose Aflibercept in Wet AMD
- KSI-301 Profile
- Analysis of the Clinical Development Program for KSI-301
- Expert Insight: KSI-301
- Expectations for Launch and Sales Opportunity of KSI-301 in Wet AMD
- OPT-302 Profile
- Key Ongoing Clinical Trials of OPT-302 in the Treatment of Wet AMD
- Analysis of the Clinical Development Program for OPT-302
- Expert Insight: OPT-302
- Expectations for Launch and Sales Opportunity of OPT-302 in Wet AMD
- Pegcetacoplan Profile
- Analysis of the Clinical Development Program for Pegcetacoplan
- Expert Insight: Pegcetacoplan
- Expectations for Launch and Sales Opportunity of Pegcetacoplan in GA
- Zimura Profile
- Analysis of the Clinical Development Program for Zimura
- Expert Insight: Zimura
- Expectations for Launch and Sales Opportunity of Zimura in GA
- ALK-001 Profile
- Analysis of the Clinical Development Program for ALK-001
- Expert Insight: ALK-001
- Expectations for Launch and Sales Opportunity of ALK-001 in GA
- RGX-314 Profile
- Key Ongoing Clinical Trials of RGX-314 in the Treatment of Wet AMD
- Analysis of the Clinical Development Program for RGX-314
- Expert Insight: RGX-314
- Expectations for Launch and Sales Opportunity of RGX-314 in Wet AMD
- Select Cell-Based Therapy Profiles
- Expert Insight: Cell-Based Therapies
- Risuteganib (Luminate) Profile
- Analysis of the Clinical Development Program for Risuteganib (Luminate)
- Expectations for Launch and Sales Opportunity of Risuteganib (Luminate) in AMD
- GB-102 Profile
- Analysis of the Clinical Development Program for GB-102
- Expectations for Launch and Sales Opportunity of GB-102 in wet AMD
- Early-Phase Pipeline Analysis
- Select Compounds in Early-Phase Development for AMD
- Key Findings
- Access and Reimbursement Overview
- Region-Specific Reimbursement Practices
- Key Market Access Considerations in Wet AMD: United States
- General Reimbursement Environment: United States
- Key Market Access Considerations in Wet AMD: EU5
- General Reimbursement Environment: EU5
- Key Market Access Considerations in Wet AMD: Japan
- General Reimbursement Environment: Japan
- Looking for More?
- Region-Specific Reimbursement Practices
- Appendix
- Dry and Wet AMD Bibliography
- Key Findings
Amanda Le, M.S., is an analyst on the CNS/Ophthalmology Disorders team at Clarivate. Prior to joining the company, she worked on research projects focusing on the effects of aging on the development of oral premalignancies, head and neck cancers, and handedness in surgery. She holds a master’s degree in medical sciences from Boston University School of Medicine and a bachelor’s degree in biochemistry from Boston College.
Andrea S. Witt, Ph.D., is Therapy Leader of the Central Nervous System and Ophthalmology Disorders Portfolio at Clarivate, where she oversees a team of Business Insights Analysts and Senior Directors responsible for market research encompassing Neurology, Psychiatry, Pain, and Ophthalmology.
Her interests beyond specific CNS indications included the market potential for neuroprotectants and the impact of biomarkers on CNS markets. Dr. Witt’s research, analysis, and commentaries have appeared in Barron’s, Pharmaceutical Executive, PharmaVoice, Nature Medicine, and CNBC. Dr. Witt’s previous experience includes 10 years of scientific research conducted on neurodegenerative disorders at Harvard Medical School/Brigham and Women’s Hospital, Duke University, and the University of Texas-Southwestern Medical Center, where she earned her Ph.D. degree.